0001209191-20-009700.txt : 20200214
0001209191-20-009700.hdr.sgml : 20200214
20200214164330
ACCESSION NUMBER: 0001209191-20-009700
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191216
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GUDONIS PAUL R
CENTRAL INDEX KEY: 0001015994
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38109
FILM NUMBER: 20621207
MAIL ADDRESS:
STREET 1: 9 HICKORY ROAD
CITY: MANCHESTER
STATE: MA
ZIP: 01944
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MYOMO INC
CENTRAL INDEX KEY: 0001369290
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-996-9058
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-16
0
0001369290
MYOMO INC
MYO
0001015994
GUDONIS PAUL R
C/O MYOMO, INC.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE
MA
02142
0
1
0
0
Chief Executive Officer
Common Stock
2019-12-16
4
A
0
1333
0.00
A
18800
D
Common Stock
2020-02-13
4
A
0
1333
0.00
A
20133
D
Common Stock
2020-02-13
4
P
0
6000
6.99
A
26133
D
Warrants
7.50
2020-02-13
4
P
0
6000
0.01
A
2020-02-13
2025-02-13
Common Stock
6000
6000
D
Reporting person was previously granted restricted stock units that may be settled into an aggregate of 6,666 shares of common stock. Upon the achievement of performance criteria, portions of the restricted stock unit grant will commence time-based vesting. The performance criteria for the restricted stock units described in this Report were met and such portion will vest in equal installments on September 25, 2020 and 2021.
Shares beneficially owned by this reporting person have been adjusted to reflect a one-for-thirty reverse stock split effected on January 30, 2020.
Represents the purchase of common stock and related investor warrant as part of the Company's underwritten public offering, which was completed on February 13, 2020. The investor warrant has an exercise price of $7.50 per share and expires five years from the date of issuance.
/s/ Paul Gudonis
2020-02-14